Physician profile
Donna Kuta
NPI 1952354391
$3,546.92
in general payments reported to CMS, 2019-2025
28 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $1,005 · 2023: $1,472 · 2024: $606 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $398.82 | 2022-2024 | Ultomiris |
| Daiichi Sankyo INC. | $307.23 | 2021-2024 | Injectafer |
| Amgen INC. | $293.76 | 2021-2023 | Evenity, Prolia, Tezspire |
| Novo Nordisk INC | $196.75 | 2025 | |
| Ferring Pharmaceuticals INC. | $159.06 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $146.59 | 2022-2024 | Saphnelo |
| Mirum Pharmaceuticals, INC. | $142.37 | 2023 | Livmarli |
| Tg Therapeutics, INC. | $141.17 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $130.84 | 2024 | |
| Vapotherm INC | $127.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2024 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $124.99 | 2023 | Gvoke Hypopen |
| Smith+Nephew, INC. | $120.83 | 2021 | |
| Biogen, INC. | $102.15 | 2023 | Tysabri, Tysabri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100.48 | 2022-2025 | |
| Pfizer INC. | $99.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $87.74 | 2022-2023 | |
| Edwards Lifesciences Corporation | $87.57 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Neurelis, INC. | $84.76 | 2023 | Valtoco |
| Glaxosmithkline, LLC. | $84.57 | 2021-2023 | Nucala |
| Inspire Medical Systems, INC. | $84.34 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $77.69 | 2023 | Entyvio, Vpriv, Elaprase |
| Melinta Therapeutics, LLC | $66.97 | 2022-2023 | Kimyrsa, Rezzayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.58 | 2022-2023 | Spevigo |
| Argenx US, INC. | $35.61 | 2023-2024 | Vyvgart |
| Eisai INC. | $22.21 | 2024 | |
| Lundbeck LLC | $16.36 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Kuta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.